Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors (ACROPOLI)
Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors Defined by a Single and Pre-specified Cutoff
Sponsor: Novartis
Listed as NCT04802876, this PHASE2 trial focuses on Anal Carcinoma and Carcinoma of Unknown Primary and remains ongoing. Sponsored by Novartis, it has been updated 8 times since 2021, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
8 versions recorded-
Apr 2025 — Present [monthly]
Active Not Recruiting PHASE2
-
Mar 2025 — Apr 2025 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2024 — Mar 2025 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Aug 2023 — Jul 2024 [monthly]
Recruiting PHASE2
Status: Active Not Recruiting → Recruiting
▶ Show 3 earlier versions
-
Nov 2022 — Aug 2023 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2021 — Nov 2022 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Apr 2021 — Sep 2021 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Novartis
- SOLTI Breast Cancer Research Group
For direct contact, visit the study record on ClinicalTrials.gov .